65 I B, drugs, pharmaceuticals, & hematology related products, FSS contract award

Active Awarded Last action

Contract number
36F79726D0181
Awardee
Awarding agency
Task orders
3

Award facts

Opportunity
Last date to order 4% complete
IDV ceiling
$5,600,000,000.00
Award type
Multiple award
Who can order
All agencies
Contracting staff
Set-aside
No set-aside
Competition
Full and Open Competition Negotiated Proposal / Quote
Pricing
Fixed Price with Economic Price Adjustment

Award details come from SAM.gov/FPDS.

About this IDV

Veterans Integrated Service Network 12 is the funding agency on a multiple-award Federal Supply Schedule contract awarded to Takeda Pharmaceuticals America, Inc. on August 15, 2026, under the GSA Pharmaceuticals and Drugs (FSS-61-IB) schedule. Agencies place orders against this catalog vehicle's price list rather than running new competitions. The award is for SIN 65 I B, Drugs, Pharmaceuticals, & Hematology Related Products, carries a $5.6 billion ceiling, runs through August 14, 2031, and used no set-aside. Takeda is a foreign-owned subsidiary of Japan-based Takeda Pharmaceutical Company Limited and holds no socioeconomic designations. The company delivers directly from its two domestic facilities in Lexington, Massachusetts and Brooks, Kentucky. The product line includes CINRYZE, KALBITOR, ADVATE, GAMMAGARD, TAKHZYRO, LIVTENCITY, GATTEX, ELAPRASE, VPRIV, FIRAZYR, and ADZYNMA, covering hereditary angioedema, hemophilia, immune deficiencies, rare genetic and metabolic conditions, and short bowel syndrome.

Recent activity under this schedule includes three firm fixed-price delivery orders from Veterans Integrated Service Network 5: $34,605.34 for GATTEX (August 25, 2026, Carrollton, Texas), $38,360.10 for TAKHZYRO 150 MG (August 27, 2026, Brooks, Kentucky), and $19,139.20 for LIVTENCITY 200 MG (August 28, 2026, Dublin, Ohio). Earlier 2026 orders came from Federal Correctional Institution Fort Worth and Veterans Integrated Service Network 20. A single-award blanket purchase agreement under this schedule carries a $231.2 million ceiling, runs from August 28, 2026 through August 27, 2027, and covers CINRYZE, KALBITOR, TAKHZYRO, ELAPRASE, VPRIV, ADZYNMA, LIVTENCITY, and GATTEX.

Task orders

Task order Ordering agency Obligated Awarded
Livtencity 200 MG 36C24526N0840 Veterans Integrated Service Network 5 (VHA) $19,139
Takhzyro 150 MG 36C24526N0865 Veterans Integrated Service Network 5 (VHA) $38,360
Gattex 5 MG 36C24526N0835 Veterans Integrated Service Network 5 (VHA) $34,605

IDV awards

IDV Agency Ceiling Awarded
36E79726A0023 BPA for cinryze, kalbitor, takhyzro, elaprase, vpriv, adzynma, livtencity, and gattex National Acquisition Center (VA) $231,177,457

Transactions

Action Obligated Date
Supplemental Agreement for work within scope P00004 · 42-2A TPR for 1 NDC $0
Supplemental Agreement for work within scope P00001 · 65IB 42-2A product addition - new package size (NPS) - independent federal ceiling price (FCP) - dual pricing $0
Original award $0

Quick answers

Who was awarded contract 36F79726D0181?

36F79726D0181 was awarded to Takeda Pharmaceuticals America, Inc. by Veterans Integrated Service Network 12 (Veterans Health Administration) on August 15, 2026.

How much is contract 36F79726D0181 worth?

36F79726D0181's own ceiling is $5,600,000,000.

How many orders have been placed under contract 36F79726D0181?

3 orders have been placed under 36F79726D0181, the latest on August 28, 2026.

Who can order from contract 36F79726D0181?

36F79726D0181 is a multiple award federal supply schedule. All agencies can place orders on it.

Is contract 36F79726D0181 part of a contract vehicle?

Yes. 36F79726D0181 is part of Pharmaceuticals and Drugs (FSS-61-IB).

Was contract 36F79726D0181 competed?

The extent of competition for 36F79726D0181 was full and open competition.

On GovTribe

See this IDV's full record

  • Every order and transaction
  • The awardee's other awards and teaming partners
  • Similar IDVs and recompete opportunities
  • Ask GovTribe AI about this IDV